A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer
A Phase 2, Open-Label, Randomized, Non-Comparative Study With Preliminary Dose Finding to Evaluate eFT508 Monotherapy or eFT508 in Combination With Avelumab in Subjects With Microsatellite Stable Relapsed or Refractory Colorectal Cancer
Sponsor: Effector Therapeutics
Listed as NCT03258398, this PHASE2 trial focuses on Microsatellite Stable Relapsed or Refractory Colorectal Cancer and remains completed. Sponsored by Effector Therapeutics, it has been updated 12 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Aug 2019 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2019 — Aug 2019 [monthly]
Active Not Recruiting PHASE2
▶ Show 7 earlier versions
-
Dec 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE2
-
Sep 2018 — Dec 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Aug 2018 — Sep 2018 [monthly]
Recruiting PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE2
-
Dec 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Oct 2017 — Dec 2017 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2017 — Oct 2017 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Effector Therapeutics
- Merck KGaA, Darmstadt, Germany
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .